- Accelerated bookbuild offering amounting to €14.9m.
- Proceeds will be used to finance clinical development of their lead product and to support exploration and development of additional business opportunities.
- Kempen & Co acted as Sole Global Coordinator and Joint Bookrunner in the transaction.
At Kempen.com, we use cookies to improve the quality of our website and service.
The investment services and investment institutions mentioned on the website may not be available in your jurisdiction or to anyone other than professional investors. More information about the countries where these investment institutions are registered and the persons to whom they may be offered can be found on the website.
Click here to view our Privacy Policy.
